MedTrace Logo

Role of Oral Zinc in Reducing Neonatal Indirect Hyperbilirubinemia

NCT06227624 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 192

Last updated 2024-01-29

No results posted yet for this study

Summary

This study aimed to determine the role of oral zinc in reducing the neonatal indirect hyperbilirubinemia if used concomitant with the standard phototherapy

Conditions

  • Neonatal Jaundice

Interventions

DRUG

Oral zinc sulfate and standard phototherapy

study the role of oral zinc sulfate in reducing level of indirect hyperbilirubinemia in neonates if used with standard phototherapy

Sponsors & Collaborators

  • National Liver Institute, Egypt

    lead OTHER

Principal Investigators

  • Heba S. Sallam, specialist · Al-Dalangat Central Hospital, Beheira, Egypt

  • Hala H. Elsaeed, professor · National liver institute. Menoufia university, Egypt

  • Mohsen H Hussein, professor · National liver institute. Menoufia university, Egypt

  • Hanaa A. El- Alraby · National liver institute. Menoufia university, Egypt

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
1 Hour
Max Age
28 Days
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-06-01
Primary Completion
2019-06-01
Completion
2020-01-01
FDA Drug
Yes

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06227624 on ClinicalTrials.gov